- Home
- LTRN vs SPRO Comparison
LTRN vs SPRO Comparison
Compare LTRN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- SPRO
- Stock Information
- Founded
- LTRN 2013
- SPRO 2013
- Country
- LTRN United States
- SPRO United States
- Employees
- LTRN N/A
- SPRO N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- SPRO Health Care
- Exchange
- LTRN Nasdaq
- SPRO Nasdaq
- Market Cap
- LTRN 46.7M
- SPRO 45.7M
- IPO Year
- LTRN 2020
- SPRO 2017
- Fundamental
- Price
- LTRN $3.31
- SPRO $0.69
- Analyst Decision
- LTRN Hold
- SPRO Buy
- Analyst Count
- LTRN 1
- SPRO 4
- Target Price
- LTRN N/A
- SPRO $5.00
- AVG Volume (30 Days)
- LTRN 25.7K
- SPRO 121.5K
- Earning Date
- LTRN 03-27-2025
- SPRO 03-27-2025
- Dividend Yield
- LTRN N/A
- SPRO N/A
- EPS Growth
- LTRN N/A
- SPRO N/A
- EPS
- LTRN N/A
- SPRO N/A
- Revenue
- LTRN N/A
- SPRO $47,977,000.00
- Revenue This Year
- LTRN N/A
- SPRO N/A
- Revenue Next Year
- LTRN N/A
- SPRO N/A
- P/E Ratio
- LTRN N/A
- SPRO N/A
- Revenue Growth
- LTRN N/A
- SPRO N/A
- 52 Week Low
- LTRN $2.79
- SPRO $0.68
- 52 Week High
- LTRN $9.36
- SPRO $1.81
- Technical
- Relative Strength Index (RSI)
- LTRN 34.43
- SPRO 35.60
- Support Level
- LTRN $3.62
- SPRO $0.75
- Resistance Level
- LTRN $4.00
- SPRO $0.80
- Average True Range (ATR)
- LTRN 0.25
- SPRO 0.05
- MACD
- LTRN -0.02
- SPRO -0.01
- Stochastic Oscillator
- LTRN 0.00
- SPRO 5.83
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.